HIVID

LOE Approaching

zalcitabine

NDAORALTABLETPriority Review
Approved
Jun 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5

Clinical Trials (5)

NCT00002333Phase 2Completed

A Study of Saquinavir and Zalcitabine, Used Alone and Together, in the Treatment of Advanced HIV Infection in Patients Who Stopped Taking or Who Cannot Take Zidovudine

900 enrolled
HIV Infections
NCT00002117Phase 3Completed

A Randomized, Open-Label Study of Alternative Treatment Combinations of Dideoxycytidine (HIVID; ddC) and Zidovudine (AZT) in Patients With HIV Infection

528 enrolled
HIV Infections
NCT00002118N/ACompleted

An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

600 enrolled
HIV Infections
NCT00001040Phase 2Completed

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

300 enrolled
HIV Infections
NCT00002347Phase 2Completed

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

225 enrolled
HIV Infections